On June 22, China Life Insurance rose 3.07% in regular trading, trading at 28.92 HKD/share, with turnover of 512 million HKD.

On the news front, Goldman Sachs recently issued a research report assigning China Life a neutral rating with a 12-month target price of 28.5 HKD, corresponding to 1.0x 2027 expected price-to-book ratio. The report noted that the strong Q2 equity market rally has already driven improvement in the company's investment performance. China Life reaffirmed its target of double-digit new business value growth for the full year, while management pledged to reduce per-share dividend volatility.

The stock had corrected over 10% from its June 15 high of 31.02 HKD, pressured by regulatory penalties on branch offices and broader market pullbacks. The current rebound reflects an oversold recovery across the insurance sector, with NCI up 2.91%, China Taiping up 2.51%, and Ping An up 0.84%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)